Emerging World Pharma, Inc.; Order of Suspension of Trading, 73509 [2012-29841]

Download as PDF Federal Register / Vol. 77, No. 237 / Monday, December 10, 2012 / Notices difference as that for other connectivity fees. Allowing a CBSX market participant that accesses both CBOE and CBSX via the same Network Access Port to only be assessed the CBOE Network Access Port fee for that port (for Disaster Recovery Network Access Port fees, as well) is reasonable because it allows such CBSX market participants that access both CBOE and CBSX via the same Network Access Port to avoid having to pay two fees for one port. This is equitable and not unfairly discriminatory because there is only one port being accessed, and because it will be applied to all CBSX market participants that access both CBOE and CBSX via the same Network Access Port. B. Self-Regulatory Organization’s Statement on Burden on Competition CBOE does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act. C. Self-Regulatory Organization’s Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others The Exchange neither solicited nor received comments on the proposed rule change. III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action The foregoing rule change has become effective pursuant to Section 19(b)(3)(A) 5 of the Act and paragraph (f) of Rule 19b–4 6 thereunder. At any time within 60 days of the filing of the proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. mstockstill on DSK4VPTVN1PROD with IV. Solicitation of Comments Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods: • Send an email to rulecomments@sec.gov. Please include File Number SR–CBOE–2012–113 on the subject line. SECURITIES AND EXCHANGE COMMISSION Paper Comments Emerging World Pharma, Inc.; Order of Suspension of Trading • Send paper comments in triplicate to Elizabeth M. Murphy, Secretary, Securities and Exchange Commission, 100 F Street NE., Washington, DC 20549–1090. All submissions should refer to File Number SR–CBOE–2012–113. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission’s Internet Web site (https://www.sec.gov/ rules/sro.shtml). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for Web site viewing and printing in the Commission’s Public Reference Room, 100 F Street NE., Washington, DC 20549, on official business days between the hours of 10:00 a.m. and 3:00 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All submissions should refer to File Number SR–CBOE– 2012–113 and should be submitted on or before December 31, 2012. For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.7 Kevin M. O’Neill, Deputy Secretary. [FR Doc. 2012–29745 Filed 12–7–12; 8:45 am] BILLING CODE 8011–01–P Electronic Comments • Use the Commission’s Internet comment form (https://www.sec.gov/ rules/sro.shtml); or 5 15 6 17 U.S.C. 78s(b)(3)(A). CFR 240.19b–4(f). VerDate Mar<15>2010 18:30 Dec 07, 2012 7 17 Jkt 229001 73509 PO 00000 CFR 200.30–3(a)(12). Frm 00109 Fmt 4703 Sfmt 4703 [File No. 500–1] December 6, 2012. It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of Emerging World Pharma, Inc. (‘‘Emerging World’’). Emerging World is a Florida corporation purportedly based in Manassas, Virginia and Sunyani, Ghana, and its stock is currently quoted on OTC Link, operated by OTC Markets Group, Inc. under the symbol EWPI. Questions have arisen concerning the adequacy and accuracy of press releases and other public statements concerning Emerging World’s business operations and financial condition. The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of Emerging World. Therefore, it is ordered, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed company is suspended for the period from 9:30 a.m. EST, on December 6, 2012 through 11:59 p.m. EST, on December 19, 2012. By the Commission. Jill M. Peterson, Assistant Secretary. [FR Doc. 2012–29841 Filed 12–6–12; 4:15 pm] BILLING CODE 8011–01–P SMALL BUSINESS ADMINISTRATION Data Collection Available for Public Comments and Recommendations 60 Day notice and request for comments. 8(a) Business Development Program. ACTION: In accordance with the Paperwork Reduction Act of 1995, this notice announces the Small Business Administration’s (SBA’s) intentions to request approval on a new information collection. DATES: Submit comments on or before February 8, 2013. ADDRESSES: Send all comments regarding whether or not this information collection is necessary for the proper performance of the function of the agency, whether or not the burden estimates are accurate, and whether or not there are ways to minimize the estimated burden and enhance the quality of the collection, to Joan SUMMARY: E:\FR\FM\10DEN1.SGM 10DEN1

Agencies

[Federal Register Volume 77, Number 237 (Monday, December 10, 2012)]
[Notices]
[Page 73509]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-29841]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[File No. 500-1]


Emerging World Pharma, Inc.; Order of Suspension of Trading

December 6, 2012.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
Emerging World Pharma, Inc. (``Emerging World''). Emerging World is a 
Florida corporation purportedly based in Manassas, Virginia and 
Sunyani, Ghana, and its stock is currently quoted on OTC Link, operated 
by OTC Markets Group, Inc. under the symbol EWPI. Questions have arisen 
concerning the adequacy and accuracy of press releases and other public 
statements concerning Emerging World's business operations and 
financial condition.
    The Commission is of the opinion that the public interest and the 
protection of investors require a suspension of trading in the 
securities of Emerging World.
    Therefore, it is ordered, pursuant to Section 12(k) of the 
Securities Exchange Act of 1934, that trading in the securities of the 
above-listed company is suspended for the period from 9:30 a.m. EST, on 
December 6, 2012 through 11:59 p.m. EST, on December 19, 2012.

    By the Commission.
Jill M. Peterson,
Assistant Secretary.
[FR Doc. 2012-29841 Filed 12-6-12; 4:15 pm]
BILLING CODE 8011-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.